Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunologic adjuvant for preventing toxoplasma infection and application of immunologic adjuvant

A technology of infection prevention and immune adjuvant, which is applied in the direction of anti-infective drugs, medical preparations containing active ingredients, bacterial antigen components, etc., and can solve problems such as unsatisfactory recombinant vaccines

Active Publication Date: 2013-05-08
LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It was found that, except for a few individual genes (such as ROP18, etc.) with better immune effects, other recombinant vaccines have unsatisfactory characteristics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunologic adjuvant for preventing toxoplasma infection and application of immunologic adjuvant
  • Immunologic adjuvant for preventing toxoplasma infection and application of immunologic adjuvant
  • Immunologic adjuvant for preventing toxoplasma infection and application of immunologic adjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0082] The immune adjuvant used for the prevention of Toxoplasma gondii infection, which uses pVAX plasmid as a carrier and is a recombinant plasmid pVAX-IL21-IL15 fused with interleukins IL21 and IL15, its base sequence is shown in SEQ ID NO: 1.

[0083] The construction method of pVAX-IL21-IL15 recombinant plasmid is as follows:

[0084] 1. Extraction of total RNA from the spleen of KM mice: Seventy-two hours after intraperitoneal inoculation of the RH strain of Toxoplasma gondii, the KM mice were killed by cervical dislocation, soaked in 75% ethanol solution for 2-3 minutes, and the spleen was removed aseptically. Put the spleen into an RNase-Free centrifuge tube, and follow-up experiments were performed according to the instructions of the RNAprep Pure Tissue Kit kit from Tiangen Biochemical Technology (Beijing) Co., Ltd.;

[0085] 2. RT-PCR amplification of the target fragment: RT-PCR amplification of IL21 and IL15 gene sequences was performed using the total RNA of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an immunologic adjuvant for preventing toxoplasma infection. The immunologic adjuvant is characterized in that the immunologic adjuvant is recombinant plasmids pVAX-IL21-IL15 formed by fusing interleukins IL21 and IL15 by using pVAX1 plasmids as carriers, and the base sequence of the immunologic adjuvant is represented by SEQ ID NO:1. The immunologic adjuvant for preventing the toxoplasma infection has a function of obviously improving the immune effect of MIC8 genes, so that the immune effect of an immune prevention vaccine against toxoplasma can be obviously enhanced.

Description

technical field [0001] The invention relates to an immune adjuvant, in particular to an immune adjuvant for preventing Toxoplasma gondii infection and application thereof. Background technique [0002] Toxoplasma gondii ( T. gondii ) is widely parasitic in the nucleated cells of a variety of mammals, and is an important pathogen of zoonotic parasitic diseases, with epidemiological characteristics of high incidence and serious harm. Infection of infants, pregnant women or immunocompromised persons can lead to miscarriage, teratogenicity or acutely acquired toxoplasmosis. AIDS is also known as Acquired Immunodeficiency Syndrome (AIDS). Studies have found that 10% to 30% of AIDS patients are complicated by toxoplasma encephalitis, which is one of the main causes of death in AIDS patients. In view of the limited ability of drugs to treat toxoplasmosis and the characteristics of large toxic and side effects, the development of vaccines, especially DNA vaccines, has gradually be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39A61K39/02A61P33/02
Inventor 朱兴全李中原陈佳徐民俊周东辉黄思扬宋慧群
Owner LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products